# Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.

> **NCT04564742** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 4017 (actual)

## Conditions studied

- Acute Myocardial Infarction
- Heart Failure

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04564742
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-22
- **Primary completion:** 2023-07-05
- **Final completion:** 2023-07-05
- **Target enrollment:** 4017 (ACTUAL)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04564742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04564742, "Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04564742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*